Loading research…
R&G PharmaStudies Co., Ltd. Class A (SZSE: 301333)
R&G PharmaStudies Co., Ltd. Class A trades on SZSE under the symbol 301333, quoted in CNY. The listing is associated with China. Its sector is Health technology, within Biotechnology. Reported figures retain their financial periods. Market prices and charts are shown separately from dated research.
- Exchange
- SZSE
- Country
- China
- Sector
- Health technology
- Industry
- Biotechnology
- Trading currency
- CNY
- ISIN
- CNE100005K44
Reported financials
Research date October 28, 2026. Figures below are dated observations, not market quotes.
| Metric | Value | Period | Period end |
|---|---|---|---|
| Revenue | 138,247,075.39 USD | TTM | Jun 30, 2026 |
| Net income | 17,697,829.82 USD | TTM | Jun 30, 2026 |
| Diluted EPS | 0.18 USD | TTM | Jun 30, 2026 |
| Total assets | 343,050,739.20 USD | Annual | Dec 31, 2025 |
| Total debt | 2,555,405.39 USD | Annual | Dec 31, 2025 |
| Gross margin | 31.13% | TTM | Jun 30, 2026 |
| Operating margin | 12.44% | TTM | Jun 30, 2026 |
| Return on equity | 6.19% | TTM | Jun 30, 2026 |
| Return on assets | 5.10% | TTM | Jun 30, 2026 |
| Dividend per share | 0.02 USD | Annual | Dec 31, 2025 |
Stock ScreenerEarnings CalendarDividends CalendarStock investing guide
Data notes
Scores, valuation models and research metrics use dated FOLITIC research. Dates and currencies remain attached to their observations. Missing values are shown as a dash.
Market quotes and charts use the separate market-data display. Saved research prices and model comparisons are not live quotes. Model ranges represent sensitivity scenarios, not confidence intervals or price guarantees.
Listings on different exchanges and different share classes are kept separate. No currency conversion is applied to saved research values.